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164 Original ResearchBACKGROUND: Smoking tobacco increases the risk of respiratory disease in adults and chil-
dren, but communicating the magnitude of these effects in a scientiﬁc manner that is
accessible and usable by the public and policymakers presents a challenge. We have therefore
summarized scientiﬁc data on the impact of smoking on respiratory diseases to provide the
content for a unique resource, SmokeHaz.
METHODS: We conducted systematic reviews and meta-analyses of longitudinal studies
(published to 2013) identiﬁed from electronic databases, gray literature, and experts. Random
effect meta-analyses were used to pool the ﬁndings.
RESULTS: We included 216 articles. Among adult smokers, we conﬁrmed substantially
increased risks of lung cancer (risk ratio (RR), 10.92; 95% CI, 8.28-14.40; 34 studies), COPD
(RR, 4.01; 95% CI, 3.18-5.05; 22 studies), and asthma (RR, 1.61; 95% CI, 1.07-2.42; eight
studies). Exposure to passive smoke signiﬁcantly increased the risk of lung cancer in adult
nonsmokers and increased the risks of asthma, wheeze, lower respiratory infections, and
reduced lung function in children. Smoking signiﬁcantly increased the risk of sleep apnea and
asthma exacerbations in adult and pregnant populations, and active and passive smoking
increased the risk of tuberculosis.
CONCLUSIONS: These ﬁndings have been translated into easily digestible content and
published on the SmokeHaz website. CHEST 2016; 150(1):164-179KEY WORDS: health risks; lung diseases; meta-analysis; passive smoking; policymakers; public
awareness; respiratory diseases; smoking; systematic reviewtional residual capacity; LRTI = lower
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Tobacco smoking is the leading cause of preventable
death in the European Union, responsible for nearly
700,000 deaths every year. Approximately 50% of
smokers die prematurely, resulting in the loss of an
average of 14 years of life.1 An estimated further 13
million people in the European Union are living in
poor health with chronic diseases as a result of smoking.
Many forms of cancer and cardiovascular and
respiratory diseases are linked to tobacco use, which
causes more problems than alcohol, drugs, high blood
pressure, excess weight, or high cholesterol. Passive
smoking is a signiﬁcant health hazard to children and
nonsmoking adults, being responsible for causing excess
cases of sudden infant death syndrome, asthma, middle
ear infections, and meningitis.2 Therefore, preventing
smoking remains a key health priority. Because smoking
prevention requires population-level policy measures
and individual treatment interventions,3 it is important
that accurate data on the effects of tobacco use on health
are readily available to policymakers, policy advocates,
and the general public.
In this respect, one major difﬁculty is that the available
evidence on smoking and health is extensive, disparate,Nottingham, City Hospital Campus NHS Trust, Hucknall Rd,
Nottingham, NG5 1PB, England; e-mail: jo.leonardi-bee@nottingham.
ac.uk
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journal.publications.chestnet.organd at times conﬂicting. Therefore, it is particularly
important that the evidence base is regularly captured,
through systematic review, and synthesized to provide
easily understandable and accurate summary estimates
of effects.
This article reports on the ﬁndings of the SmokeHaz
project, which summarizes the harms of smoking on
respiratory health in a freely accessible online resource
for policymakers, researchers, students, health care
professionals, and the public.4 SmokeHaz is a
collaborative project between the UK Centre for
Tobacco and Alcohol Studies, the European Respiratory
Society, and the European Lung Foundation. In this
project, all of the available worldwide literature up to
2013 has been used to update a series of systematic
reviews and meta-analyses on associations between
tobacco smoking and a range of respiratory health
outcomes. This article presents the detailed scientiﬁc
data for validation by independent peer review and is
designed to promote and strengthen public awareness of
tobacco control issues as requested in Article 12 of the
World Health Organization’s Framework Convention on
Tobacco Control.3Methods
Inclusion Criteria
We included longitudinal, cohort, or nested case-control studies that
assessed the effect of active or passive tobacco smoking on the risk
of developing respiratory diseases. Outcomes of interest included
lung cancer, COPD, asthma and wheeze, asthma exacerbations, or
sleep apnea or tuberculosis in adults and asthma and wheeze,
asthma exacerbations, lung function, sleep apnea, or lower
respiratory tract infection (LRTI) in children. Where possible we
used biochemically veriﬁed measures of smoking, for example
exhaled carbon monoxide or saliva cotinine levels, in preference to
self-reported smoking status. Active smoking was deﬁned as ever
smoker, current smoker, or ex- or former smoker; passive smoking
was deﬁned as being in contact with secondhand smoke from any
source: domestic, occupational, or other sources. Studies assessing
levels of exposure to smoke based on cigarette consumption (pack
years deﬁned as number of packs smoked per day multiplied by
number of years smoked, duration of smoking, or the number of
cigarettes smoked per day) were also included. For passive smoking,
we included studies which assessed effects either in non- or never
smokers or where the effect of active smoking was adjusted for in
the statistical analyses. In addition to adult populations, studiesfocusing on in utero, infants, children, and adolescents were also
included. Where insufﬁcient studies were identiﬁed for particular
outcomes, we extended our searches to include studies reporting
disease-speciﬁc mortality. Studies which only looked at passive
smoke exposure relating to cooking fuels and those looking at active
or passive smoking from illegal substances were excluded. To ensure
the strictest independence of the science as far as possible within the
limits of disclosed knowledge, we omitted any primary studies with
declared or identiﬁable involvement of the tobacco industry.
Search Strategy
Comprehensive literature searches in MEDLINE, Embase, and Web of
Science were conducted from 1985 to 2013 (precise end dates varied
for each health outcome), with no language restrictions imposed. We
also searched conference proceedings from major international
tobacco control conferences and a range of websites hosted by
relevant professional societies. Contact with experts in the ﬁeld was
made to identify further relevant published or unpublished research.
References lists of all included studies were screened to identify
further potentially eligible studies.
Study Selection and Data Extraction
Titles, abstracts, and full-text articles identiﬁed from the searches were
screened by one reviewer (L. J.) to select relevant articles. A second
reviewer (J. L.-B.) independently screened a minimum of 10% of
titles and abstracts and 30% of full-text articles. Two authors (L. J.
and J. L.-B.) independently extracted data from included studies
using previously piloted data extraction forms and independently
assessed the quality of the included studies using the Newcastle-
Ottawa Scale5 for primary studies and the Assessment of Multiple
Systematic Reviews Scale for existing systematic reviews.6 A
Newcastle-Ottawa Scale score of $ 7 indicated high quality in the165
primary studies. Disagreements and discrepancies in study selection
and data extraction were resolved through discussion.
Statistical Analyses
We extracted measures of effect for the association between exposure to
smoking and the risk of disease using either ORs, risk ratios (RRs),
hazard ratios, or incidence rate ratios, with 95% CIs. Estimates
adjusted for potential confounders were used in preference to crude
estimates. Pooled relative RRs were estimated using random effect
meta-analyses. Heterogeneity between the studies was assessed usingTABLE 1 ] Characteristics of Studies Included in the Syste
Diseases
Tobacco
Smoking
No. of
Studies Refere
Adult
Lung cancer Active 34 10-4
Passive 15 44-5
COPD Active 24 59-8
Passive 3 72, 84
Asthma Active 8 88-9
Asthma exacerbations Active 2 97,
Passive 3 99-1
Tuberculosis Active 4 102-1
Passive 2 104,
Sleep apnea Active 3 112, 11
Passive 2 114,
Childhood
LRTI Passive 34 118-1
Asthma/wheeze Passive 71 15
Lung function in infants Passive 13 154-1
Lung function in school-aged
children
Passive 12 167-1
Data are No. (%) or as otherwise indicated. LRTI ¼ lower respiratory tract inf
aOne study was conducted in both the United Kingdom and the United States.
bAssessed based on adjustment for confounders.
166 Original Researchthe I2 statistic.7 Subgroup analyses were performed to explore reasons
for heterogeneity based on sex, age of children, country (Europe
compared with the rest of the world), methodologic quality, and level
of exposure (eg, pack years of active smoking). Evidence of
publication bias was assessed using funnel plots. The P values < .05
were considered statistically signiﬁcant. Statistical analysis was
performed using STATA version 11 (StataCorp) and Review Manager
5.3 (Cochrane). The reviews adhered to the Meta-analysis of
Observational Studies in Epidemiology8 and the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses guidelines.9Results
The main ﬁndings from the systematic reviews and
meta-analyses are presented. The characteristics of the
studies included in the systematic reviews are presented
in Table 1. Tables giving more information about the
study populations and wider data, including funnel
plots, and additional ﬁgures containing more detailed
data are available on the SmokeHaz website.4
Lung Cancer
Active Smoking: Thirty-four studies assessing the
effect of active smoking vs nonsmoking on the
development of lung cancer were eligible for inclusion
in the review.10-43 Nineteen (56%) studies were deemed
to be of high quality; 13 were conducted in Europe.Smokers were 11 times more likely than nonsmokers to
develop lung cancer (RR, 10.92; 95% CI, 8.28-14.40;
I2 ¼ 95%; 34 studies) (Fig 1).10-43 The results were
similar in both the higher- and lower-quality studies.
Higher risks of developing lung cancer were seen in
women (12-fold increase) than men (nine-fold increase);
however, the test for subgroup differences was not
statistically signiﬁcant (P ¼ .40). Studies conducted in
European countries tended to show higher risks of lung
cancer (15-fold increase) among smokers than those
conducted elsewhere (nine-fold increase), but not
reaching signiﬁcance (P value for subgroup differences,
P ¼ .06). All of the included studies reported that the
incidence of lung cancer was consistently greater in those
with higher cigarette consumption. A pooled analysis inmatic Reviews
nces
Used a
Cohort
Design
Conducted
in Europe
Assessed as
High
Quality
Published
Since 2000
3 27 (79) 13 (38) 19 (56) 22 (65)
8 13 (91) 4 (27) 6 (40) 8 (53)
2 22 (92) 15 (63) 5 (21) 20 (83)
, 85 3 (100) 1 (33) 0 (0) 0 (0)
5 8 (100) 6 (75) 4 (50) 3 (38)
98 1 (50) 1 (50) 2 (100) 2 (100)
01 3 (100) 2 (67)a 1 (33) 2 (67)
05 4 (100) 0 (0) 3 (75) 4 (100)
106 2 (100) 0 (0) 2 (100) 2 (100)
3, 116 3 (100) 2 (67) 0 (0) 1 (33)
115 2 (100) 2 (100) 0 (0) 1 (50)
51 34 (100) 17 (50) 16 (47) 16 (47)
3 71 (100) 32 (45) 31 (44) 55 (77)
66 13 (100) 7 (57) 6 (46)b 5 (38)
78 12 (100) 4 (33) 0 (0) 6 (50)
ection.
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Study or Subgroup
Relative Risk Ratio
IV, Random, 95% CI
Relative Risk Ratio
IV, Random, 95% CI
1.1.1 Lung cancer
Active smoking
Passive smoking
10.92
1.41
1.1.2 Chronic Obstructive Pulmonary Disease (COPD)
Active smoking (3.18-5.05)
(1.07-2.42)
4.01
1.61
1.97
1.1.3 Adult asthma
Active smoking
1.1.4 Sleep apnoea
Active smoking (1.02-3.82)
0.1 0.2 0.5 1 2
Exposure increased riskExposure decreases risk
5 10
1.1.5 Tuberculosis (TB)
Active smoking
Passive smoking
1.57
1.44
(8.28-14.40)
(1.21-1.65)
(1.18-2.10)
(1.02-2.04)
Figure 1 – Summary estimates from meta-analyses assessing the effect of active and passive smoking on the risk of lung cancer, COPD, asthma, sleep
apnea, and tuberculosis in adults.the 13 comparisons from 11 studies10-12,16,25,26,31-33,35,37
that reported pack years found a signiﬁcant dose response
relationship between increasing risk (from threefold to
12-fold) of development of lung cancer with increasing
exposure (< 20 pack years: RR, 3; 20-40 pack years: RR, 7;
40-60 pack years: RR, 11; > 60 pack years: RR, 12).
Passive Smoking: Fifteen studies44-58 that assessed the
effect of passive smoking on the risk of lung cancer were
included in the review. Six (40%) were deemed to be of
higher quality. The main results are based on data from
13 of the studies (two studies45,47 were excluded because
of using duplicate data).
Exposure to passive smoke increased the risk of
developing lung cancer by 1.41-fold (41%) compared
with never smokers unexposed to passive smoke
(RR, 1.41; 95% CI, 1.21-1.65; I2 ¼ 0%; 13 studies)
(Fig 1).44,46,48-58 Most of this evidence was based on data
from nonsmoking women who were exposed to passive
smoke from their smoker husbands (11 of the studies).
Similar risks of lung cancer were seen in European
countries compared with studies conducted elsewhere in
the world and in higher-quality studies compared with
lower-quality studies. A meta-analysis to investigate the
effect of levels of exposure to passive smoke was possible
in four studies,48,51,52,54 which found women whose
husbands smoked > 20 cigarettes per day had a
1.46-fold (46%) increased risk of lung cancer than
women with nonsmoker husbands (RR, 1.46; 95% CI,
1.10-1.44; four studies).journal.publications.chestnet.orgCOPD
Active Smoking: Twenty-four studies59-82 assessing the
effect of smoking on the risk of developing COPD were
identiﬁed from a previous systematic review83 and an
updated search; however, only 22 of the studies provided
sufﬁcient data to be included in the meta-analysis.
Most (n ¼ 13) of the included studies used the Global
Initiative for Chronic Obstructive Lung Disease criteria
to deﬁne COPD based on FEV1/FVC < 70%. Only ﬁve
of the studies (21%) were deemed to be of high quality.
Smokers were 4.01 times more likely to develop
COPD than nonsmokers (RR, 4.01; 95% CI, 3.18-5.05,
I2 ¼ 87%; 22 studies) (Fig 1).59-68,70,72-82 Similar risks
of COPD were seen between men and women, in
higher- and lower-quality studies, and between studies
conducted in Europe and the rest of the world.
Passive Smoking: Three studies72,84,85 assessing the
effect of passive smoking on the risk of COPD were
identiﬁed from two previous systematic reviews86,87
and an updated search. COPD was deﬁned as either
FEV1 < 65%, FEV1/maximum FVC < 65% or percent
predicted FEV1 < 75%, or as a clinical diagnosis of acute
obstructive disease. None of the studies were deemed to
be of high quality.
In adults, exposure to passive smoking for at least
1 h/d was associated with a 1.44-fold (44%) increased
risk of COPD compared with non-smokers (RR, 1.44;
95% CI, 1.02-2.01)85; however, another study found no167
consistent effect of passive smoking on the development
of COPD in nonsmokers.72 Exposure to passive smoking
during childhood and adulthood was associated with a
1.72-fold (72%) increased risk of developing COPD in
adulthood (RR, 1.72; 95% CI, 1.31-2.23); however, no
increased risk was seen in those only exposed during
childhood.84
Adult Asthma
Eight studies88-95 assessing the effect of active smoking
on the risk of asthma in adults were identiﬁed from a
previous systematic review.96 Asthma was ascertained
through physician reports in most studies, whereas two
studies relied on self-reports. Four of the studies (50%)
were deemed to be of high quality. All but two of the
included studies91,95 were conducted in Europe.
Smokers were 1.61 times (61%) more likely to develop
asthma than adults who had never smoked (RR, 1.61;
95% CI, 1.07-2.42; I2 ¼ 91%; eight studies) (Fig 1).88-95
The high level of heterogeneity appeared to be related to
a low-quality study,91 which reported a signiﬁcantly
reduced risk of asthma in smokers. A sensitivity analysis
excluding this study91 found smokers were 1.81 times
(81%) more likely to develop asthma than people who
never smoked (RR, 1.81; 95% CI, 1.37-2.38; I2 ¼ 68%;
seven studies). The risk of developing asthma from
active smoking was similar between European and non-
European studies and between higher- and lower-quality
studies.
Asthma Exacerbations
Five studies97-101 were identiﬁed for inclusion which
assessed the effect of active and passive smoking on
exacerbations of asthma in adults, pregnant women, or
children. Three of the studies (60%) were deemed to be
of high quality.
Active Smoking: Two studies assessed the effect of
active smoking on asthma exacerbations.97,98 Adults
with asthma who were current or ex-smokers had a 1.71
times higher risk of subsequent asthma exacerbations
than adults with asthma who had never smoked (RR,
1.71; 95% CI, 1.48-1.97; one study).97 A study of 80
pregnant women with asthma found that being a current
smoker or ex-smoker signiﬁcantly increased the number
of severe asthma exacerbations per year, and being a
current smoker also resulted in poorer asthma control
compared with those who never smoked.98
Passive Smoking: Three studies assessed the effect
of passive smoking on asthma exacerbations.99-101
In nonsmoking adults, exposure to passive smoke168 Original Researchsigniﬁcantly increased the risk of being restricted in daily
activities (RR, 1.61; 95% CI, 1.06-2.46; one study),100 but
had no signiﬁcant effect on increased risk of cough,
shortness of breath, or being awakened by asthma91 or
on admission to hospital for asthma.99 In a study of 140
children with asthma between 3 and 15 years of age,
exposure to passive smoke in the household or by the
mother more than doubled the risk of multiple hospital
admissions for asthma per year (RR, 2.55; 95% CI, 1.12-
5.82; one study), and exposure to maternal smoking more
than tripled the risk of multiple hospital admissions for
asthma per year (RR, 3.25; 95% CI, 1.13-8.85).101
TB
Five studies102-106 assessing the effect of active and
passive smoking on the risk of developing TB were
identiﬁed from four previous systematic reviews107-110
and an updated search. Four of the studies (80%) were
deemed to be of high quality. None of the studies were
conducted in Europe.
Active Smoking: Four studies assessed the effect of
active smoking.102-105 People who smoked were 1.57
times (57%) more likely to develop TB than those who
had never smoked (RR, 1.57; 95% CI, 1.18-2.10;
I2 ¼ 93%; four studies) (Fig 1). Signiﬁcantly higher risks
of TB from smoking were seen from the higher-quality
studies (2.2 times) compared with the study with a lower
quality (1.1 times) (test for subgroup differences,
P < .00001); however, similar risks were seen in studies
of men and women. All of the studies reported an
increased risk of TB with increasing numbers of
cigarettes smoked per day.
Passive Smoking: Two studies assessed the effect of
passive smoking.104,106 Exposure to household tobacco
smoke increased the risk of developing TB by 1.44 times
(44%) compared with people who were unexposed to
household tobacco smoke (RR, 1.44; 95% CI, 1.02 to
2.04; I2 ¼ 0%; two studies). Both of the included studies
were deemed to be of high quality, and similar results
were seen for men and women. However, no signiﬁcant
trend was seen between the increased frequency of
exposure to passive smoke (numbers of days per week
exposed) and the risk of TB (P ¼ .74).104
Sleep Apnea
Five studies111-116 assessing the effect of active and
passive smoking on the risk of sleep apnea were
identiﬁed from a previous review117 and an updated
search. None of the included studies were deemed to be
of high quality.[ 1 5 0 # 1 CHE S T J U L Y 2 0 1 6 ]
Active Smoking: Three studies assessed the effect of
active smoking on the development of sleep apnea in
adults.112,113,116 Two of these studies reported numerical
data, which found that people who smoke are twice as
likely to have sleep apnea than those that do not smoke
(RR, 1.97; 95% CI, 1.02-3.82; two studies).113,116 Men
and women were found to have similar risks of sleep
apnea from smoking (1.5-fold increase) when compared
with nonsmokers.116 One study investigated the
intensity of exposure and found a dose-dependent
relationship where the greatest risk of sleep apnea was
associated with smoking at least 40 cigarettes per day
(RR, 8.38; 95% CI, 1.68-41.94; one study).113
Passive Smoking: Two studies assessed the effect of
passive smoking on the risk of development of sleep
apnea in infants or young children.114,115 Maternal
smoking during pregnancy approximately doubled the
risk of their infant developing sleep apnea (age range,
1 day to 29 weeks) (RR, 1.76; 95% CI, 1.17-2.64; one
study).114 Maternal smoking after birth signiﬁcantly
increased the risk of developing sleep apnea in infants
between the ages of 6 and 18 months (RR, 1.25; 95% CI,
1.06-1.47; one study).115 One study114 also reported
signiﬁcantly more infants developed sleep apnea
where both parents had smoked during pregnancy
compared with only mothers smoking during pregnancy
(P ¼ .007).
LRTI in Childhood
Thirty-four studies118-151 assessing the effect of passive
smoking on the risk of LRTI in children < 2 years of age
were identiﬁed from a previous review152 and an
updated search. Eighteen studies considered the effects
of any household member smoking: six of both parents
smoking, nine of paternal smoking, 16 of maternal
smoking, and 11 of prenatal maternal smoking (some
studies covered more than one exposure). Sixteen (47%)
studies were deemed to be of high quality, and 17 were
conducted in Europe.Study or Subgroup
Relative Risk Ratio
IV, Random, 95% CI
Household
Both parents
Prenatal maternal
Postnatal maternal
Paternal
1.82
1.43
1.15
1.62
1.19
(1.51-2.19)
(1.28-1.59)
(0.97-1.36)
(1.46-1.79)
(1.10-1.29)
0.5
E
Figure 2 – Summary estimates from meta-analyses assessing the effect of pa
journal.publications.chestnet.orgInfants exposed to smoking by any household member
were 1.43 times (43%) more likely to develop LRTI than
those not exposed to smoking in the home (RR, 1.43;
95% CI, 1.28-1.59; I2 ¼ 45%; 18 studies) (Fig 2).
Similar risks of LRTI were seen in European studies
(1.42 times) and non-European studies (1.46 times)
and in higher-quality (1.49 times) and lower-quality
(1.35 times) studies.
Signiﬁcant increased risks of developing LRTI were also
seen in infants exposed to both parents smoking (RR,
1.82; 95% CI, 1.51-2.19; I2 ¼ 45%; six studies), prenatal
maternal smoking (RR, 1.19; 95% CI, 1.10-1.29;
I2 ¼ 78%; 11 studies), and maternal smoking in the
postnatal period (RR, 1.62; 95% CI, 1.46-1.79; I2 ¼ 50%;
16 studies), but not to paternal smoking (RR, 1.15;
95% CI, 0.97-1.36; I2 ¼ 51%; nine studies).
Childhood Asthma and Wheeze
Seventy-one studies assessing the effect of passive
smoking in the risk of developing asthma or wheeze in
childhood were identiﬁed from a recent systematic
review.153 Thirty one of the studies (44%) were deemed
to be of high quality, and 32 were conducted in Europe.
Wheeze in Childhood: Children # 2 years of age who
had been exposed to prenatal maternal smoking had a
1.41 times (41%) increased risk of developing wheeze
compared with unexposed children (RR, 1.41; 95% CI,
1.19- 1.67) (Fig 3). Similar effects were observed for the
relationship between prenatal maternal smoking and the
incidence of wheeze in children between 3 and 4 years of
age (1.28 times) and 5 and 18 years (1.52 times) of age.
Similar effect sizes were seen in children between 5 and
18 years of age who were exposed to paternal smoking
(1.39 times) and in children exposed to household
tobacco smoke (1.32 times).
The strongest impact on the incidence of wheeze was
seen in children exposed to postnatal maternal smoking,
where children < 5 years of age exposed to postnatalRelative Risk Ratio
IV, Random, 95% CI
0.7 1
Exposure increased riskxposure reduces risk
1.5 2
ssive smoking on the risk of lower respiratory tract infection in infants.
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Study or Subgroup
Relative Risk Ratio
IV, Random, 95% CI
Relative Risk Ratio
IV, Random, 95% CI
0.5 0.7 1
Exposure increases riskExposure decreases risk
1.5 2
1.1.1 Prenatal maternal smoking
0-2 years of age
3-4 years of age
5-18 years of age
1.41 (1.19-1.67)
1.28 (1.14-1.44)
1.52 (1.24-1.87)
1.1.2 Postnatal maternal smoking
0-2 years of age
3-4 years of age
5-18 years of age
1.70 (1.23-2.35)
1.65 (1.20-2.27)
1.18 (0.99-1.41)
1.1.3 Paternal smoking
5-18 years of age 1.39 (1.04-1.85)
1.1.4 Household smoking
0-2 years of age
3-4 years of age
5-18 years of age
1.35 (1.10-1.66)
1.06 (0.88-1.28)
1.32 (1.12-1.56)
Figure 3 – Summary estimates from meta-analyses assessing the effect of exposure to passive smoking on the risk of developing wheeze in children.maternal smoking were 1.65 to 1.70 times (65%-70%)
more likely than unexposed children to develop wheeze
(# 2 years: pooled RR, 1.70; 95% CI, 1.23-2.35; 3-4
years: RR, 1.65; 95% CI, 1.20-2.27).
For all sources of exposure to smoking (prenatal,
postnatal, paternal, and household), the effect size for
the increased risk of wheeze was similar in sensitivity
analyses based methodologic quality and geographic
location of the studies, except for the following
sensitivity analyses: In European studies, the magnitudes
of the risks of wheeze from prenatal maternal smoking
in children < 2 years of age were larger (2.21 times) than
all studies (1.41 times). For children between 3 and 4
years of age, a larger magnitude of risk of household
smoking on the risk of wheeze was seen in higher quality
studies (1.20 times) than all studies (1.06 times).
Asthma in Childhood: Children # 2 years of age who
were exposed to prenatal maternal smoke were 1.85 times
(85%) more likely to develop asthma than unexposed
children (RR, 1.85; 95% CI, 1.35-2.54) (Fig 4). However,
smaller magnitudes of risk were seen in children between
3 and 4 years of age (1.30 times) and those between 5 and
18 years of age (1.23 times). Across the age groups,
children exposed to household smoking were 1.14 to
1.30 times (14%-30%) more likely to develop asthma.
However, exposure to postnatal maternal or paternal
smoke did not appear to consistently increase the risk
of developing asthma in any age group.
For all sources of exposure to smoking (prenatal,
postnatal, paternal, and household), the effect size for170 Original Researchthe increased risk of asthma was similar in sensitivity
analyses based methodologic quality and geographic
location of the studies, except for the following
sensitivity analyses: In European studies, the magnitudes
of the risks of asthma from postnatal maternal smoking
in children between 5 and 18 years of age were larger
(1.48 times) than all studies (1.20 times). In children
between 5 and 18 years of age, the magnitude of the risk
of asthma from exposure to household smoking was
larger (2.02 times) than all studies (1.30 times).Lung Function in Childhood
Infants: Thirteen studies154-166 assessing the effect of
exposure to passive smoking on lung function in infants
were identiﬁed from a previous review2 and an updated
search. Lung function measurements were assessed
within 8 weeks of birth in all studies. Seven studies were
conducted in Europe.
Prenatal Exposure: Seven of the studies assessed the
effect of prenatal exposure of infants to maternal
smoking on maximal ﬂow at functional residual capacity
(FRC), with most ﬁnding no signiﬁcant
reductions.155,159,160,162,166 However, the two remaining
studies found prenatal maternal smoking signiﬁcantly
reduced maximal ﬂow at FRC.158,165 Prenatal maternal
smoking had no signiﬁcant effect on FRC at 8 weeks of
age.156 Prenatal maternal smoking was signiﬁcantly
associated with reduced tidal breathing ratio (tPTEF:tE
[time to reach peak tidal expiratory ﬂow as a proportion
of total expiratory time]) in the infants within 1 week[ 1 5 0 # 1 CHE S T J U L Y 2 0 1 6 ]
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Figure 4 – Summary estimates from meta-analyses assessing the effect of exposure to passive smoking on the risk of developing asthma in children.after birth163 and in those born preterm at 37 weeks’
gestation,159 but no association between tidal breathing
ratio in infants and maternal smoking was seen in the
other studies.155-157 No apparent effect of prenatal
smoking was seen on infant respiratory system
compliance,156,157,159,165 except for one study were
respiratory system compliance was reduced in boys but
not girls.161 Prenatal maternal smoking reduced lung
function (FEV0.5 [forced expiratory volume in 0.5
seconds]), in infants at 6 weeks of age.154
Postnatal Exposure: Postnatal maternal smoking
signiﬁcant reduced airﬂow during inspiration and
expiration in their infants as measured by speciﬁc
conductance and hence potentially increased
susceptibility to asthma and/or COPD.157 However,
maternal postnatal smoking was not associated with
bronchial responsiveness in their infants154,155 or a
reduction in lung volume.156,158,161 Paternal smoking
during pregnancy had no signiﬁcant impact on various
measures of lung function (tidal volume, respiratory
rate, minute ventilation, and time to peak expiratory
ﬂow).164
School-Aged Children: Twelve studies167-178 assessing
the effect of passive smoking on lung function in
school-aged children were identiﬁed from a previous
review2 and an updated search. None of the studies were
deemed to be of high quality, and only four studies were
conducted in Europe.journal.publications.chestnet.orgPrenatal Exposure: Individual studies found smoking
during pregnancy was signiﬁcantly associated with
children having a 62-mL reduction in FEV1 and 53-mL
reduction in FVC at age 5 years of age174 and
signiﬁcantly lowered peak expiratory ﬂow at 8 years of
age167; however, no signiﬁcant effect on lung function
was seen in other studies.168,171
Postnatal Exposure: Any parental smoking signiﬁcantly
reduced FEV/FVC ratios by 0.67% and forced expiratory
ﬂow during the midportion of the FVC by 2% and
signiﬁcantly increase FVC by 0.58%, but had no effect
on FEV1 (two studies) (Fig 5).
171,178 Data from
individual studies showed postnatal maternal smoking
had no signiﬁcant effect on measures of lung
function167,172,173,176; however, continual maternal
smoking during and after pregnancy signiﬁcantly
reduced some measures of lung function (FEV/FVC and
forced expiratory ﬂow during the midportion of the
FVC), with similar magnitudes of reductions seen in
boys and girls.171 Furthermore, having both parents
smoke resulted in signiﬁcantly lower FEV1/FVC ratios in
boys, but not in girls; but no effect was seen for only
exposure to paternal smoking.176 In another study,
exposure to smoke measured using cotinine levels in
hair resulted in signiﬁcant decreases in peak expiratory
ﬂow, but not FEV1.
175
Three of the included studies assessed the effect of
exposure to smoking on lung growth169,170,177; however,171
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Figure 5 – Meta-analysis for the effect of passive smoke exposure on lung function in school-aged children. FEF25-75 ¼ forced expiratory ﬂow during
the midportion of the FVC; LF ¼ lung function.no consistent effect of parental or household smoking
on lung function assessment of lung growth was
demonstrated. Exposure to household smoking resulted
in a signiﬁcant increase in lung growth by 7 mL in girls,
but signiﬁcantly reduced growth by 12 mL in boys.169
Having both parents smoke resulted in a signiﬁcant
reduction in lung growth in children between 8 and 9
years of age, but no effect was seen at older ages or in
those with one parental smoker.170 However in another
study, maternal smoking signiﬁcantly reduced the
expected annual lung growth.177Discussion
After decades of public skepticism among tobacco
smokers, this millennium has seen major advances in
public awareness that tobacco smoking poses a risk to172 Original Researchhealth as a result of highly successful tobacco control
policies and public information campaigns.3,179-181
However, the battle to ensure the public fully
understands the health risks of tobacco smoking is far
from won. The public and policymakers are well aware
that lung cancer is one of the greatest risks of tobacco
smoking. However, there is little awareness of the risk of
other diseases from active and passive smoking, and
few parents understand the damage their smoking can
do to their children.180 This lack of knowledge remains
a major challenge for policymakers. Without full
understanding of the risks, smokers are less likely to
have the motivation to quit, even when effective
smoking cessation measures are readily available.182,183
The data presented in this article provide policymakers,
the public, and health professionals with an easy one-stop[ 1 5 0 # 1 CHE S T J U L Y 2 0 1 6 ]
shop where they can ﬁnd evidence-based meta-analyses
of pooled data from studies published to 2013, on the
relationship between tobacco smoking and increased
risks of respiratory diseases in adults and in children. The
main ﬁndings from our updated systematic reviews and
meta-analyses are subsequently discussed.
As previously mentioned, it is recognized that the public
knows smoking increases the risk of lung cancer1;
however, they have little knowledge of the level of the
risk, where smokers are 11 times more likely to develop
lung cancer, and there is no safe minimum number of
cigarettes per day. More education and publicity is
needed to increase public awareness of these very high
risks. Exposure to passive smoke increased the risk of
lung cancer in nonsmokers by 1.41 times. Raising public
awareness about lung cancer is also important because
motivation to quit may be improved through better
awareness and knowledge about the symptoms of lung
cancer; the lack of a curative treatment; the catastrophic
effect on life expectancy, with only 12.6% of patients
being alive 5 years after diagnosis; and lung cancer now
being the leading cause of cancer deaths worldwide in
both men and women.181
It is estimated that 40% to 50% of lifelong smokers will
develop COPD181; however, the exact mechanism by
which tobacco smoking causes or promotes COPD is
not known. Furthermore, the general public have little
knowledge of this disease and its increased risk as a
result of smoking. We found smokers are 4.01 times
more likely to develop COPD, and nonsmokers exposed
to passive smoking had 1.44 to 1.72 fold increased risk of
developing COPD. However, the latter ﬁnding is only
based on data from three studies; therefore, more
research is needed to better deﬁne the relationship
between passive smoking and the risk of development of
COPD and to establish whether there are differential
effects based on whether passive smoke exposure occurs
in childhood or adulthood.
Tobacco smoking is not generally thought of as a risk
factor for asthma; therefore, the public should be made
aware that adult smokers are 1.61 times more likely to
develop asthma, and adult smokers are 1.71 times more
likely to have asthma exacerbations. We found pregnant
women with asthma who smoke have more asthma
exacerbations per year and poorer asthma control, and
children exposed to passive smoke are more than twice
as likely to have multiple hospital admissions.
Although there has been a major reduction in the
prevalence and incidence of TB in past decades, thejournal.publications.chestnet.orgthreat of TB is now growing once again because of the
emergence of new strains that are resistant to anti-TB
drugs. With the inevitable threat of multidrug-resistant
TB increasing across Europe, it is important for
policymakers to learn of any preventative measures,
large or small, that might contribute to reducing this
emerging new threat. Therefore, it is important that we
highlight the need to raise public awareness in relation
to our ﬁndings that (1) adults smokers are 1.57 times
more likely to develop TB, (2) the risk of TB increases
with increasing consumption of cigarettes per day for a
longer period of time, and (3) nonsmokers who are
exposed to passive smoke have a 1.44 times increased
risk of developing TB. This evidence provides a motivator
to ensure effective smoking-cessation programs are
provided for in populations who live in regions identiﬁed
as at especially high risk of TB.
The role of smoking on the risk of sleep apnea is
currently unclear. We found adult smokers were 1.97
times as likely to develop sleep apnea, and the risk could
be as great as 8.38 times when at least 40 cigarettes are
smoked per day. We also found maternal smoking
during pregnancy increased the risk of sleep apnea in
infants by 1.76 times; postnatal maternal smoking
increased the risk of sleep apnea in childhood by 1.25
times. Our review indicates that smoking is a signiﬁcant
contributory factor to sleep apnea, but the evidence base
is limited and needs strengthening. Therefore, efforts
should be made to increase public awareness of the link
between smoking and sleep apnea.
LRTIs are an especial problem in childhood.181 We
found the risk of infants developing LRTI was
signiﬁcantly increased from their exposure to passive
smoking within the household, where the largest
increase in risk (1.82-fold) was from both parents
smoking. We also found prenatal exposure to maternal
smoking increased the risk of LRTI by 1.19-fold.
Policymakers are already aware of the harm passive
smoking can do to children, and they should be
informed that smoke-free legislation has already led to a
decrease in passive smoke exposure, with a corresponding
reduction in hospital admissions of children with
respiratory tract infections.184
Regarding childhood asthma and wheeze, exposure to
passive smoking in the home environment signiﬁcantly
increased the risk of developing asthma and/or wheeze,
where the largest increases in risk seemed to be from
maternal prenatal smoking on asthma in infants < 2
years of age (1.85-fold) and maternal postnatal smoking173
on wheeze in children < 5 years of age (up to 1.70-fold).
The ﬁndings indicate that passive smoking has a greater
effect on the risk of wheeze in children across all age
groups than on the risk of asthma, where infants < 2
years of age are at greater risk. More research is needed
to understand the mechanisms underlying these effects
and the components of tobacco smoke involved. It is
encouraging that adoption of comprehensive smoke-free
legislation has led to a signiﬁcant reduction in the rate of
hospital admissions for childhood asthma.185
Regarding lung function, we found exposure to passive
smoking can decrease lung function in infants within
8 weeks of birth and in school-aged children. The
ﬁndings of these studies were variable, and most lung
function measurements were normal. The only ﬁndings
of note were that exposure of infants to maternal
smoking after birth is associated with reduced airﬂow,
which may reﬂect the reported increased susceptibility
of children to the various airways diseases previously
discussed, and that maternal smoking during pregnancy
and parental smoking after birth may have a detrimental
effect on lung function in school-aged children.
However, there is currently insufﬁcient evidence to
reach ﬁrm conclusions on the effect of prenatal and
postnatal parental smoking on lung function of their
children.
The strength of our systematic reviews is that methodologic
quality of the evidence within the systematic reviews
was generally good, with most of the more recent
studies providing adjusted effect estimates, thereby
reducing the potential for confounding within our
pooled estimates. We are conﬁdent that our search
strategies were comprehensive, and we were able to
identify further eligible studies through contact with
experts with an interest in tobacco control within the
respiratory medicine ﬁeld. A limitation of the systematic
reviews relates to the high levels of heterogeneity found
within some comparisons; however, we performed174 Original Researchexploration analyses using subgroup and sensitivity
analyses to assess whether the association varied by
participant-level characteristics (age and sex) and
study-level characteristics (geographic location and
methodologic quality) and found relatively consistent
ﬁndings across these subgroups.Conclusions
SmokeHaz provides a useful resource enabling
policymakers and others to rapidly view the available
evidence-based scientiﬁc data on the increased risk of
development of respiratory diseases in adults and
children caused by active and passive tobacco smoking.
The high levels of risk reported support smoke-free
legislation and justify its continuance and expansion, not
only in public places, but also in the home and other
conﬁned spaces (eg, cars), to protect children. All
governmental efforts against smoking should be
strengthened, with the ultimate aim of phasing out
tobacco use. Because of the now indisputable health
hazards, measures to help all current smokers to quit
should be widely available to the general public and
to patients suffering from smoking-related diseases,
ensuring cost is not a barrier. Education to disseminate
information to increase public awareness of the many
health risks of smoking should be improved, and
education and training on the health risks and in
smoking cessation methods should be included in
the curricula of all health professionals and medical
students. The SmokeHaz systematic review of
respiratory health risks of smoking and its companion
free public website4 are ideal as educational resources
because they aim to promote and strengthen public
awareness of tobacco control issues, therefore
complying with Article 12 (education, communication,
training, and public awareness) of the World Health
Organization’s Framework Convention on Tobacco
Control.3[ 1 5 0 # 1 CHE S T J U L Y 2 0 1 6 ]
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